Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Sanofi's Itepekimab?
Itepekimab is a monoclonal antibody commercialized by Sanofi, with a leading Phase III program in Chronic Obstructive Pulmonary Disease (COPD)....
Data Insights
Itepekimab by Regeneron Pharmaceuticals for Bronchiectasis: Likelihood of Approval
Itepekimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Bronchiectasis. According to GlobalData, Phase II...